The evidence base for supplementation in patients with AMD favors an AREDS2* formulation, but without dangerous levels of Zinc, and using a supplement that contains all three macular carotenoids in a MZ:L:Z (mg) ratio of 10:10:2. The only such commercially available supplement is MacuHealthPLUS+.
MacuHealthPLUS+= AREDS2* formulation, with two important distinctions, as follows:
Reduced Zinc from 80mg to 25mg, thereby compliant with RDA (recommended dietary allowance) and therefore precluding the possibility of any increased risk for disease progression in AMD patients with a particular genetic background. Of note, AREDS2* has shown that there was no significant difference between the AMD group who received 25mg of zinc compared to the AMD group who received 80mg of zinc (in terms of benefits), supporting further the decision to recommend a lower (25mg) zinc dose for patients with AMD.
The addition of 10mg of Meso-Zeaxanthin (the third and centrally dominant macular carotenoid), thereby facilitating maximum augmentation of macular pigment and facilitating optimization of visual performance in eyes with AMD.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Discount Code Available by Request for Current Patients!